Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea |
Kim, Seong Heon
(Department of Pediatrics, Pusan National University Children's Hospital)
Lim, Taek Jin (Department of Pediatrics, Pusan National University Children's Hospital) Song, Ji Yeon (Department of Pediatrics, Pusan National University Children's Hospital) Kim, Su Young (Department of Pediatrics, Pusan National University Children's Hospital) |
1 | Kaito H, Kamei K, Kikuchi E, Ogura M, Matsuoka K, Nagata M, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of RTX, steroids and ciclosporin. Pediatr Nephrol 2010;25:957-9. DOI |
2 | Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. RTX in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012;23:1117-24. DOI |
3 | Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating RTX to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007;2:932-7. DOI |
4 | Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of RTX for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009;24:1321-8. DOI |
5 | Fujinaga S, Hirano D, Nishizaki N, Kamei K, Ito S, Ohtomo Y, et al. Single infusion of RTX for persistent steroid-dependent minimalchange nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010;25:539-44. DOI |
6 | Ito S, Kamei K, Ogura M, Udagawa T, Fujinaga S, Saito M, et al. Survey of RTX treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2013;28:257-64. DOI |
7 | Niu X-L, Hao S, Wang P, Zhang W, Guo G-M, Wu Y, et al. Single dose of RTX in children with steroid-dependent minimal change nephrotic syndrome. Biomed Rep 2016;5:237-42. DOI |
8 | Tellier S, Brochard K, Garnier A, Bandin F, Llanas B, Guigonis V, et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 2013;28:911-8. DOI |
9 | Cornec D, Tempescul A, Querellou S, Hutin P, Pers J-O, Jamin C, et al. Identification of patients with indolent B cell lymphoma sensitive to RTX monotherapy. Ann Hematol 2012;91:715-21. DOI |
10 | Igarashi T, Kobayashi Y, Ogura M, Kinoshita T, Ohtsu T, Sasaki Y, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with RTX: a Japanese phase II study. Ann Oncol 2002;13:928-43. DOI |
11 | Ahn YH, Kang HG, Lee JM, Choi HJ, Ha I-S, Cheong HI. Development of antiRTX antibodies in children with nephrotic syndrome. Pediatr Nephrol 2014;29:1461-4. DOI |
12 | Chaumais M-C, Garnier A, Chalard F, Peuchmaur M, Dauger S, Jacqz-Agrain E, et al.Fatal pulmonary fibrosis after RTX administration. Pediatr Nephrol 2009;24:1753-5. DOI |
13 | Sellier-Leclerc A-L, Belli E, Guerin V, Dorfmuller P, Deschenes G. Fulminant viral myocarditis after RTX therapy in pediatric nephrotic syndrome. Pediatr Nephrol 2013;28:1875-9. DOI |
14 | Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of RTX in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908. DOI |
15 | Ehrich JHH, Geerlings C, Zivicnjak M, Franke D, Geerlings H, Gellermann J. Steroid-resistant idiopathic childhood nephrosis: overdiagnosed and undertreated. Nephrol Dial Transplant 2007; 22:2183-93. DOI |
16 | Kyrieleis HAC, Lowik MM, Pronk I, Cruysberg HRM, Kremer JAM, Oyen WJG, et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol CJASN 2009;4:1593-600. DOI |
17 | Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. RTX treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008;23:1269-79. DOI |
18 | Bagga A, Sinha A, Moudgil A. RTX in patients with the steroidresistant nephrotic syndrome. N Engl J Med 2007;356:2751-2. DOI |
19 | Gilbert RD, Hulse E, Rigden S. RTX therapy for steroid-dependent minimal change nephrotic syndrome. Pediatr Nephrol 2006;21: 1698-700. DOI |
20 | Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of RTX. Arthritis Rheum 2004;50:2580-9. DOI |
21 | Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after RTX therapy. Pediatr Nephrol 2004;19:794-7. DOI |
22 | Sinha A, Bhatia D, Gulati A, Rawat M, Dinda AK, Hari P, et al. Efficacy and safety of RTX in children with difficult-to-treat nephrotic syndrome. Nephrol Dial Transplant 2015;30:96-106. DOI |
23 | Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after RTX for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012;27:1910-5. DOI |
24 | Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. RTX for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2014;384:1273-81. DOI |
25 | Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with RTX for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010;5:2207-12. DOI |